PASI 75 response over time in FIXTURE study. 3 Green and orange arrows... | Download Scientific Diagram
Major Secondary Endpoints: Moderate to Severe Plaque PsO | TREMFYA® (guselkumab) HCP
A multicenter, randomized, open-label pilot trial assessing the efficacy and safety of etanercept 50 mg twice weekly followed by etanercept 25 mg twice weekly, the combination of etanercept 25 mg twice weekly
Time course of PASI 75, PASI 90, sPGA 0/1, and DLQI overall score of... | Download Scientific Diagram
Novartis' Cosentyx™ two-year data shows sustained effect and favorable safety profile in psoriasis patients | Novartis
Injectable Agents in Development for Psoriasis
Solved Health State transition PASI 75 maintain PASI 75 PASI | Chegg.com
Long-term data on the proposed adalimumab biosimilar BCD-057 in patients with moderate to severe psoriasis: A randomized controlled trial | PLOS ONE
SKYRIZI® Efficacy In Moderate to Severe Plaque Psoriasis (Ps)
Proportions of patients who achieved (a) PASI-75 and (b) PASI-50 and... | Download Scientific Diagram
JCM | Free Full-Text | Use of Guselkumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: A 1 Year Real-Life Study
Deucravacitinib superior to placebo, apremilast in phase 3 plaque psoriasis trials
Novartis' plaque psoriasis drug keeps skin clear 4 years post treatment
Figure 2 | Efficacy and Safety of Brodalumab in Patients with Moderate-to-Severe Plaque Psoriasis and Skin of Color: Results from the Pooled AMAGINE-2/-3 Randomized Trials | SpringerLink
SOTYKTU™ (deucravacitinib) Efficacy | for HCPs
PASI-75 Response with Otezla in the Treatment of Moderate to Severe Plaque Psoriasis — Efficacy | Otezla® (apremilast) Healthcare Professional Site
Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis | NEJM
Improvement in Psoriasis Symptoms and Physical Functioning with Secukinumab Compared with Placebo and Etanercept in Subjects with Moderate-to-Severe Plaque Psoriasis and Psoriatic Arthritis: Results of a Subanalysis from the Phase 3 Fixture
Plaque Psoriasis Efficacy | Enbrel® (etanercept)
a) PASI-75 response rate for the North American population through... | Download Scientific Diagram
PASI 75, PASI 90, and PASI 100 response at week 12 for patients... | Download Scientific Diagram
Figure 2 | Exposure–Response Relationships for the Efficacy and Safety of Risankizumab in Japanese Subjects with Psoriasis | SpringerLink
Plaque Psoriasis Skin Clearance | COSENTYX® (secukinumab)
Plaque Psoriasis Efficacy | Enbrel® (etanercept)
Pediatric Psoriasis Before & After Results | Taltz® (ixekizumab)
